Key result
There was no significant difference in all-cause mortality and cardiovascular hospitalization among patients with CHF assigned to 2.5, 5, or daily doses of carvedilol.
Why the study?
Does a higher dose of carvedilol (5 mg or 20 mg) improve clinical outcomes compared to a low dose (2.5 mg) in Japanese patients with mild to moderate chronic heart failure?
RCT (n=364)
stratified
Does a higher dose of carvedilol (5 mg or 20 mg) improve clinical outcomes compared to a low dose (2.5 mg) in Japanese patients with mild to moderate chronic heart failure?
A low dose of carvedilol (2.5 mg) is as effective as higher doses for clinical outcomes in mild to moderate CHF, provided it achieves reductions in heart rate and BNP.
Answers are grounded in this paper and cite their sources.
Low-dose carvedilol matches higher doses for outcomes in mild-moderate CHF if HR and BNP respond; extends dose-finding data to Japanese patients.
BACKGROUND: In chronic heart failure (CHF), it remains unclear whether the minimal dose of beta-blockade is related to survival benefits and which parameter predicts morbidity and mortality. We sought to determine the minimal dose related to survival benefits by comparing the efficacy and safety of three doses of carvedilol and the best predictive parameter for effective outcomes in Japanese patients with CHF. METHODS: In this prospective, randomized, stratified trial, 364 patients with mild to moderate CHF were assigned to a daily carvedilol dose of 2.5, 5, or 20mg, plus optimal standard therapy. FINDINGS: During the mean 3-year follow-up, resting heart rate (HR) and BNP were significantly reduced with dose-response relations in the early period but without dose-response relations in the late period. The LVEF and the LVDd were increased and decreased, respectively, without a dose-response relation. No significant difference was seen in the composite primary endpoint of all-cause mortality and hospitalization for cardiovascular diseases and heart failure. Multivariate analysis indicated early decreases in HR and BNP predicted long-term outcomes. However, adverse events increased dose-dependently. Among 237 polymorphisms in 87 heart failure-related genes, the osteopontin G-156 del genotype was associated with an event-free survival rate (Wilcoxon test, P=0.030). CONCLUSIONS: A low carvedilol dose is effective if the HR and/or plasma BNP has been reduced. Carvedilol therapy should be guided by reductions in HR and/or BNP, especially by initial HR reduction, but not only by its dose. OPN might be a surrogate genetic marker for long-term event-free survival.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2012) conducted an RCT in mild to moderate chronic heart failure (n=364). Carvedilol vs. Different doses (2.5, 5, or 20 mg) was evaluated on composite of all-cause mortality and hospitalization for cardiovascular diseases and heart failure. There was no significant difference in all-cause mortality and cardiovascular hospitalization among patients with CHF assigned to 2.5, 5, or daily doses of carvedilol.
Synapse has enriched 10 related papers. Consider them for comparative context: